Use of anakinra in severe COVID-19: a case report

dc.creator	Filocamo, Giovanni
dc.creator	Mangioni, Davide
dc.creator	Tagliabue, Paola
dc.creator	Aliberti, Stefano
dc.creator	Costantino, Giorgio
dc.creator	Minoia, Francesca
dc.creator	Bandera, Alessandra
dc.date.accessioned	2020-06-24T13:30:26Z
dc.date.available	2020-06-24T13:30:26Z
dc.date.issued	2020-07
dc.description.abstract	Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).	pt_BR
dc.identifier.citation	FILOCAMO, G. et al. Use of anakinra in severe COVID-19: a case report. International Journal of Infectious Diseases, [S.l.], v. 96, p. 607-609, July 2020.	pt_BR
dc.identifier.uri	https://repositorio.ufla.br/handle/1/41555
dc.identifier.uri	https://www.sciencedirect.com/science/article/pii/S1201971220303337	pt_BR
dc.language	en_US	pt_BR
dc.publisher	Elsevier	pt_BR
dc.rights	openAccess	pt_BR
dc.source	International Journal of Infectious Diseases	pt_BR
dc.subject	Anakinra	pt_BR
dc.subject	COVID-19 - Treatment	pt_BR
dc.title	Use of anakinra in severe COVID-19: a case report	pt_BR
dc.type	Artigo	pt_BR

Arquivos

Agora exibindo 1 - 1 de 1